Case Report of an 11 year old male with gigantism and acromegaly without demonstratable growth hormone hypersecretion or increase in the insulin-like growth factor-1 axis
Nicholas Jospe, MD
Growth Hormone Administration Reduces Visceral Adiposity and HsCRP in Patients with Growth Hormone Deficiency Following Cure of Acromegaly: A Randomized, Placebo-Controlled Study
Karen K. Miller, MD
The Clinical Features and Therapeutic Outcomes in 110 Patients with Acromegaly at a Single Institute
I Fukuda, N Hizuka, M Kurimoto, J Morita, S Tanaka, Y Yamakado, and K Takano
Impact of Metabolic Factors on IGF-1 Levels in Treated Acromegalic Patients with Divergent GH/IGF-1 Level
M Matta, V Bongard, S Grunenwald, J-C Maiza, A Bennet, and P Caron
High-Dose Octreotide LAR Is Effective and Safe in Patients with Acromegaly Inadequately Controlled by Conventional Somatostatin Analog Therapy: A Randomized, Controlled Trial
Gherardo Mazziotti, MD